How Many People Are on Mounjaro — and What Does That Mean for You?

Tirzepatide — the active substance in Mounjaro — was originally approved for type 2 diabetes management and has since received regulatory approval for chronic weight management in a number of countries. Since weight-management approval, prescribing volumes have climbed steeply in many regions. In the UK alone, tens of thousands of prescriptions were issued within the first year of the weight-management indication becoming available, and comparable growth has been reported across Europe, North America, and beyond.

Wegovy (semaglutide), another once-weekly injectable medicine in the same therapeutic class, has followed a similar trajectory. When considered together, the number of people on weight-loss injections like Mounjaro now runs into the millions globally — a scale that has created both high demand and, in some markets, supply pressures that prescribers and patients have had to navigate.

Why are so many people being prescribed it?

These medicines act on appetite-regulating pathways — Mounjaro as a dual GIP and GLP-1 receptor agonist — which commonly leads to reduced appetite and a greater sense of fullness. Many people find this makes it easier to eat less without constant hunger. Because the effect addresses a physiological driver of weight gain rather than relying on willpower alone, prescribers have found it a clinically meaningful option for people who meet the criteria set by their national health authority.

Suitability is always determined by a prescriber on an individual basis — it is not appropriate for everyone. If you are curious about what life on Mounjaro is actually like for people who have been prescribed it, that experience varies considerably from person to person.

Is the number still growing?

Yes, by most available indicators. Regulatory approvals have been broadening — for example, to include cardiovascular risk reduction in certain patient groups — which has widened the prescribing population. Awareness has also grown significantly, partly driven by high-profile media coverage and, in some cases, public discussion of whether well-known figures are taking Mounjaro. That public attention has translated into more people discussing the option with their own prescribers.

Being one of millions on the same medication is reassuring in some ways — there is a substantial and growing body of shared experience to draw on — but your journey is still individual. Dose titration, side effects, weight progress, and how the medicine fits around your lifestyle all differ from person to person, and those details matter most when they are your own.

GLP Trackr is built specifically for people already prescribed Mounjaro or Wegovy. The most immediate way it helps is through progress and body tracking: log your weight, measurements, mood, energy, and food-noise levels in a quick daily check-in, and watch the trends emerge over weeks rather than guessing from day to day. Alongside that, the insights feature draws on your own logged data to surface patterns — for example, how your sleep or protein intake correlates with how you feel — giving you something concrete to discuss at your next prescriber appointment.

For a broader picture of managing your Mounjaro prescription, the app brings dose logging, side-effect tracking, and progress charts into one place, so nothing gets lost across sticky notes and memory.

GLP Trackr is available on the App Store and Google Play — give it a try free for 7 days and see your own data start to take shape.

GLP Trackr provides general information and tracking tools only. Any questions about your prescription, dose, or suitability should always be directed to your prescriber or doctor — they know your full medical history and are best placed to advise you.